Severe candidal balanoposthitis on concurrent treatment with secukinumab and the antidiabetic agent empagliflozin (sodium-glucose cotransporter 2 inhibitor - SGLT2-inhibitor)

J Dtsch Dermatol Ges. 2019 Apr;17(4):456-458. doi: 10.1111/ddg.13807. Epub 2019 Mar 15.

Authors

I Moldenhauer¹, R U Pliquett², B Kreft³, C Sunderkötter³

Affiliations

¹ Department of Dermatology and Venereology, University Medical Center, Martin Luther University of Halle-Wittenberg. New address: Department of Internal Medicine I, University Medical Center, Halle (Saale), Germany.
² Department of Internal Medicine II, University Medical Center, Martin Luther University of Halle-Wittenberg. New address: Department of Nephrology and Diabetology, Carl-Thiem Medical Center, Cottbus, Germany.
³ Department of Dermatology and Venereology, University Medical Center, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany.

PMID: 30873750
DOI: 10.1111/ddg.13807

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Administration, Oral
Angioedema / chemically induced
Angioedema / diagnosis
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use
Antifungal Agents / administration & dosage
Antifungal Agents / therapeutic use
Benzhydryl Compounds / adverse effects
Benzhydryl Compounds / therapeutic use
Candida albicans / isolation & purification
Candidiasis, Oral* / drug therapy
Candidiasis, Oral* / microbiology
Candidiasis, Oral* / pathology
Fluconazole / administration & dosage
Fluconazole / therapeutic use
Foreskin / pathology
Glucosides / adverse effects
Glucosides / therapeutic use
Humans
Male
Middle Aged
Missed Diagnosis
Penis / pathology
Sodium-Glucose Transporter 2 Inhibitors / administration & dosage
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antifungal Agents
Benzhydryl Compounds
empagliflozin
Fluconazole
Glucosides
secukinumab
Sodium-Glucose Transporter 2 Inhibitors